News
We bring you up to date at all times: Discover the latest news from the chemical industry, analytics, lab technology and process engineering. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of the chemical industry: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 64,557 keywords from chemistry, pharmaceutics, material sciences and related science disciplines in the encyclopedia.
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.chemeurope.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
09-Aug-2005 - Mayne Group Limited advises that the Federal Court of Australia (Victorian Division) has ruled that Mayne Pharma's formulation of Epirubicin infringes a patent of the innovator - Pharmacia Italia S.P.A. (a subsidiary of Pfizer, Inc.). Mayne will consider appealing this ruling. In addition, Mayne ...
04-Aug-2005 - Pfizer Inc announced that Leslie Mays recently joined the company as vice president of global diversity and inclusion. In this new position, Mays is responsible for developing and leading the design and implementation of global diversity strategies and plans for Pfizer. Mays has a broad range of ...
05-Jul-2005 - ALTANA und Pfizer haben vereinbart, die Daxas® (Roflumilast)-Kooperation zum 30. Juni 2005 zu beenden. Gemäß der Vereinbarung gibt Pfizer alle bezüglich Daxas® bestehenden Rechte an ALTANA zurück. ALTANA übernimmt die alleinige Verantwortung für die weitere Entwicklung von Daxas®, insbesondere ...
05-Jul-2005 - Following the announcement of the termination of the Daxas® (roflumilast) collaboration with Pfizer, ALTANA disclosed the top line results of the first one-year COPD study of Daxas®. The phosphodiesterase4 (PDE4)-inhibitor Daxas® is an oral investigational, steroid free anti-inflammatory agent ...
20-Apr-2005 - Pfizer Inc opened a $35 million state-of-the-art clinical research unit (CRU) to confirm the safety and action of potential new medicines. The 62,500 square-foot, 3-story facility includes 50 beds and employs about 50 staff. At the CRU, study volunteers will receive potential medicines that have ...
31-Mar-2005 - Pfizer Inc said that it will appeal a decision by the Austrian Patent Office to invalidate the company's enantiomer patent covering atorvastatin calcium, the active ingredient in Lipitor. Lipitor is sold in Austria under the brand name, Sortis. Pfizer said it is confident it will, on appeal, be ...
28-Feb-2005 - Pfizer Inc announced that it has entered into an agreement to acquire Idun Pharmaceuticals Inc, a biopharmaceutical company focused on the discovery and development of therapies to control apoptosis, a process of cell death that occurs in a broad range of diseases. Financial terms of the ...
Public Citizen Charge is Misleading and Unfair to Patients
03-Feb-2005 - Pfizer Inc said that it remains confident in its COX-2 medicines as important treatment options for arthritis patients and that it has acted responsibly in sharing all appropriate data with the U.S. Food and Drug Administration. Pfizer vigorously refutes claims by Public Citizen that safety data ...
30-Jan-2004 - Tripos, Inc. announced an amendment to its strategic collaboration with Pfizer Inc. for the design, synthesis and purification of druglike compounds. Tripos will reduce file enrichment activities with Pfizer, but partially offsetting this reduction, Tripos will engage in new work for Pfizer in ...
14-Jan-2004 - Pfizer Consumer Healthcare, a division of Pfizer Inc, announced that it will explore strategic options for approximately 60 of its non-core consumer products in Europe, including the possible sale of these products. The majority of these products are small brands, sold in single markets only. ...
© 1997-2024 LUMITOS AG, All rights reserved